tirzepatide breast cancer study Weight-loss wonder drug Mounjaro/Zepbound shrinks tumors GLP-1 Receptor Agonists in Breast

NYT's opinion page: science can't keep pace with how people are actually using these drugs

The clinical features of this condition include childhood obesity, hyperphagia, infantile hypotonia, hypogonadism, short stature, and characteristic facial features

Adults with overweight or obesity taking the once-weekly GIP/GLP-1 receptor agonist tirzepatide achieved a mean weight loss of at least 16% at 72 weeks, according to topline results from the SURMOUNT-1 clinical trial

Our primary and urgent care experts provide personalized treatment plans to help you achieve better health

The gut microbiome, body weight, and related comorbidities are intricately linked through a complex interaction of microbial, genetic, environmental, and psychological factors

Wegovy vs Ozempic: Which semaglutide is right for you